These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 7589206)
1. Regional haemodynamic effects of platelet activating factor in the rat. King KA; Lim SL; Pang CC Eur J Pharmacol; 1995 Aug; 281(2):187-93. PubMed ID: 7589206 [TBL] [Abstract][Full Text] [Related]
2. Beneficial effects of TCV-309, a novel potent and selective platelet activating factor antagonist in endotoxin and anaphylactic shock in rodents. Terashita Z; Kawamura M; Takatani M; Tsushima S; Imura Y; Nishikawa K J Pharmacol Exp Ther; 1992 Feb; 260(2):748-55. PubMed ID: 1738121 [TBL] [Abstract][Full Text] [Related]
3. Effect of the platelet-activating factor antagonist, TCV-309, and the cyclo-oxygenase inhibitor, ibuprofen, on the haemodynamic changes in canine experimental endotoxic shock. Yamanaka S; Iwao H; Yukimura T; Kim S; Miura K Br J Pharmacol; 1993 Dec; 110(4):1501-7. PubMed ID: 8306093 [TBL] [Abstract][Full Text] [Related]
4. Involvement of nitric oxide and eicosanoids in platelet-activating factor-induced haemodynamic and haematological effects in dogs. Noguchi K; Matsuzaki T; Shiroma N; Ojiri Y; Sakanashi M Br J Pharmacol; 1996 Jun; 118(4):941-50. PubMed ID: 8799566 [TBL] [Abstract][Full Text] [Related]
5. Inhibitory effect of TCV-309, a novel platelet activating factor (PAF) antagonist, on endotoxin-induced disseminated intravascular coagulation in rats: possible role of PAF in tissue factor generation. Kawamura M; Terashita Z; Imura Y; Shino A; Nishikawa K Thromb Res; 1993 May; 70(4):281-93. PubMed ID: 8332959 [TBL] [Abstract][Full Text] [Related]
6. Platelet-activating factor receptor antagonist attenuates endotoxin-induced vascular hyporeactivity in the pithed rat. Yoshikawa D; Shiga T; Saito S; Morita T; Imai T; Goto F Eur J Pharmacol; 1998 Jan; 342(2-3):241-5. PubMed ID: 9548392 [TBL] [Abstract][Full Text] [Related]
7. Regional haemodynamic effects of urocortin in the anaesthetized rat. Abdelrahman AM; Pang CC Eur J Pharmacol; 2003 Apr; 466(3):317-21. PubMed ID: 12694815 [TBL] [Abstract][Full Text] [Related]
8. The roles of platelet-activating factor and endothelin-1 in renal damage after total hepatic ischemia and reperfusion. Suzuki S; Serizawa A; Sakaguchi T; Tsuchiya Y; Kojima Y; Okamoto K; Kurachi K; Konno H; Fujise Y; Baba S; Nakamura S Transplantation; 2000 Jun; 69(11):2267-73. PubMed ID: 10868624 [TBL] [Abstract][Full Text] [Related]
9. Extended lung preservation with platelet-activating factor-antagonist TCV-309 in combination with prostaglandin E1. Qayumi AK; English JE; Duncan S; Ansley DM; Pearson B; Nikbakht-Sangari M; Sammartino C; Fradet G J Heart Lung Transplant; 1997 Sep; 16(9):946-55. PubMed ID: 9322146 [TBL] [Abstract][Full Text] [Related]
10. Effect of TCV-309, a novel platelet activating factor antagonist, on hemodynamics in dogs with endotoxin-induced shock. Okano S; Tagawa M; Urakawa N J Vet Med Sci; 1995 Apr; 57(2):385-7. PubMed ID: 7492672 [TBL] [Abstract][Full Text] [Related]
11. Pressor effects of the alpha 2-adrenoceptor agonist B-HT 933 in anaesthetized and haemorrhagic rats: comparison with the haemodynamic effects of amidephrine. MacLean MR; Thomson M; Hiley CR Br J Pharmacol; 1989 Jun; 97(2):419-32. PubMed ID: 2569342 [TBL] [Abstract][Full Text] [Related]
12. Cardiac functional and structural alterations induced by endotoxin in rats: importance of platelet-activating factor. Iwase M; Yokota M; Kitaichi K; Wang L; Takagi K; Nagasaka T; Izawa H; Hasegawa T Crit Care Med; 2001 Mar; 29(3):609-17. PubMed ID: 11373429 [TBL] [Abstract][Full Text] [Related]
13. Pharmacological profile of TCV-309--a potent PAF antagonist. Terashita Z; Takatani M; Nishikawa K J Lipid Mediat; 1992; 5(2):183-5. PubMed ID: 1445598 [TBL] [Abstract][Full Text] [Related]
14. Effect of platelet activating factor (PAF) on blood flow distribution in the spontaneously hypertensive rat. Goldstein BM; Gabel RA; Huggins FJ; Cervoni P; Crandall DL Life Sci; 1984 Sep; 35(13):1373-8. PubMed ID: 6482659 [TBL] [Abstract][Full Text] [Related]
16. Platelet activating factor causes hyperconstriction at the inflammatory coronary lesions in pigs in vivo. Kozai T; Shimokawa H; Yamawaki T; Fukumoto Y; Kadokami T; Kuwata K; Katsumata N; Egashira K; Takeshita A Coron Artery Dis; 1997 Jul; 8(7):423-32. PubMed ID: 9383603 [TBL] [Abstract][Full Text] [Related]
17. Effects of TCV-309, a novel PAF antagonist, on circulatory shock and hematological abnormality induced by endotoxin in dogs. Kawamura M; Kitayoshi T; Terashita Z; Fujiwara S; Takatani M; Nishikawa K J Lipid Mediat Cell Signal; 1994 May; 9(3):255-65. PubMed ID: 7921785 [TBL] [Abstract][Full Text] [Related]
18. Systemic and regional hemodynamic changes during endotoxin or platelet activating factor (PAF)-induced shock in rats. Mulder MF; van Lambalgen AA; van Kraats AA; Scheffer PG; Bouman AA; van den Bos GC; Thijs LG Circ Shock; 1993 Dec; 41(4):221-9. PubMed ID: 8143350 [TBL] [Abstract][Full Text] [Related]
19. Platelet-activating factor antagonist TCV-309 attenuates the induction of the cytokine network in experimental endotoxemia in chimpanzees. Kuipers B; van der Poll T; Levi M; van Deventer SJ; ten Cate H; Imai Y; Hack CE; ten Cate JW J Immunol; 1994 Mar; 152(5):2438-46. PubMed ID: 8133055 [TBL] [Abstract][Full Text] [Related]
20. Platelet activating factor (PAF) inhibitor (TCV-309) reduces caerulein- and PAF-induced pancreatitis. A morphologic and functional study in the rat. Tomaszewska R; Dembiński A; Warzecha Z; Banaś M; Konturek SJ; Stachura J J Physiol Pharmacol; 1992 Dec; 43(4):345-52. PubMed ID: 1294265 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]